Tren Konsumsi Obat Kardiovaskular di Komunitas di Surabaya Timur Selama Tahun 2020-2022: Studi Farmakoepidemiologi Deskriptif

Trend in Cardiovascular Medicine Consumption in a Community in East Surabaya from 2020 to 2022: a Descriptive Pharmacoepidemiological Study

Authors

  • Sylvi Irawati Universitas Surabaya Author
  • Silvia Universitas Surabaya Author
  • Deisy Author
  • I Gusti Ayu Putri Maharani Universitas Surabaya Author
  • Putu Ayu Sintya Pradnya Dewi Universitas Surabaya Author

DOI:

https://doi.org/10.30872/jsk.v7i2.953

Keywords:

defined daily dose, drug utilization, kardiovaskular, komunitas, konsumsi

Abstract

Tren konsumsi obat kardiovaskular pada populasi di Indonesia masih belum banyak diketahui. Data ini sangat penting untuk mengidentifikasi potensi masalah pencegahan dan pengobatan penyakit kardiovaskular. Penelitian bertujuan menganalisis tren konsumsi obat kardiovaskular selama tahun 2020–2022 di komunitas di Surabaya Timur. Desain penelitian adalah farmakoepidemiologi deskriptif menggunakan database penjualan obat kardiovaskular di apotek. Rata-rata kunjungan pasien rawat jalan (KPRJ) adalah 132.547 per tahun. Volume konsumsi dihitung menggunakan Anatomical Therapeutic Classification/Defined Daily Dose (ATC/DDD) World Health Organization (WHO). Konsumsi total seluruh obat kardiovaskular di komunitas menunjukkan tren peningkatan signifikan secara statistik dari 923,12 DDD/100.000 KPRJ/hari pada tahun 2020 menjadi 1935,52 DDD/100.000 KPRJ/hari pada tahun 2022 (p < 0,001) dengan laju pertumbuhan per tahun sebesar 27,99%. Agents acting on the renin-angiotensin system dan amlodipine adalah kontributor utama bagi total konsumsi obat kardiovaskular setiap tahun. Dibutuhkan penelitian lebih lanjut terkait optimalisasi pengendalian faktor risiko dan keamanan penggunaan obat kardiovaskular risiko tinggi di komunitas.

References

[1] T. Vos et al., "Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019," The Lancet, vol. 396, no. 10258, pp. 1204–1222, 2020.

[2] N. Mboi et al., "The state of health in Indonesia's provinces, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019," The Lancet Global Health, vol. 10, no. 11, pp. e1632–e1645, 2022.

[3] L. H. Goh et al., "The epidemiology and burden of cardiovascular diseases in countries of the Association of Southeast Asian Nations (ASEAN), 1990–2021: findings from the Global Burden of Disease Study 2021," The Lancet Public Health, vol. 10, no. 6, pp. e467–e479, 2025.

[4] F. R. Muharram et al., "The 30 years of shifting in the Indonesian cardiovascular burden—analysis of the global burden of disease study," Journal of Epidemiology and Global Health, vol. 14, no. 1, pp. 193–212, 2024.

[5] S. E. Vollset et al., "Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021," Lancet, vol. 403, pp. 2204–56, 2024.

[6] Badan Pusat Statistik. (2023). Kepadatan penduduk menurut provinsi (jiwa/km2). [Online] Available: https://www.bps.go.id/id/statistics-table/2/MTQxIzI=/kepadatan-penduduk-menurut-provinsi.html

[7] Dinas Kesehatan Provinsi Jawa Timur. (2020). Profil Kesehatan Provinsi Jawa Timur.

[8] Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan Republik Indonesia. (2023). Survei Kesehatan Indonesia (SKI) dalam angka.

[9] D. M. Yaputra, Y. I. Wibowo, L. Aditama, C. Brata, and S. Irawati, "Faktor-faktor yang mempengaruhi ketidaksesuaian pemberian statin pada first-user statins di Apotek UBAYA," MPI, vol. 5, no. 1, 2023.

[10] Kelompok Kerja Prevensi dan Rehabilitasi Kardiovaskular Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. (2022). Panduan Prevensi Penyakit Kardiovaskular Aterosklerosis.

[11] F. Visseren et al., "2021 ESC guidelines on cardiovascular disease prevention in clinical practice," European Heart Journal, vol. 42, pp. 3227–337, 2021, doi: 10.1093/eurheartj/ehab-484.

[12] V. K. Yan et al., "Trends in cardiovascular medicine use in 65 middle-and high-income countries," Journal of the American College of Cardiology, vol. 77, no. 7, pp. 1021–1023, 2021.

[13] B. L. Strom, S. Kimmel, and S. Hennesy, Eds. Pharmacoepidemiology, 6 ed. Hoboken, NJ: Wiley-Blackwell, 2020.

[14] M. Sabaté and E. Montané, "Pharmacoepidemiology: an overview," Journal of Clinical Medicine, vol. 12, no. 22, p. 7033, 2023. [Online]. Available: https://www.mdpi.com/2077-0383/12/22/7033.

[15] A. Sommet and A. Pariente, "Methods in pharmacoepidemiology," Therapies, vol. 74, no. 2, pp. 187–197, 2019.

[16] EUPATI. "Epidemiology and pharmacoepidemiology." https://learning.eupati.eu/course/view.php?id=47 (accessed.

[17] Data for Impact (D4I). Number of outpatient department visits per 10,000 population per year. [Online] Available: https://www.data4impactproject.org/

[18] WHO Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD Index 2025. [Online] Available: https://atcddd.fhi.no/atc_ddd_index/

[19] WHO Collaborating Centre for Drug Statistics Methodology. (2025). Guidelines for ATC classification and DDD assignment 2025.

[20] S. Hollingworth and T. Kairuz, "Measuring medicine use: applying ATC/DDD methodology to real-world data," Pharmacy, vol. 9, no. 1, p. 60, 2021. [Online]. Available: https://www.mdpi.com/2226-4787/9/1/60.

[21] R. Roimawati, "Analisis Kuantitas Penggunaan Obat-obat Kardiovaskular untuk Pasien Rawat Jalan di RSUD Panembahan Senopati Bantul Selama Tahun 2013-2017 dengan Metode ATC/DDD dan DU90%," Universitas Islam Indonesia, 2020.

[22] U. Bergman et al., "Drug utilization 90%–a simple method for assessing the quality of drug prescribing," European journal of clinical pharmacology, vol. 54, no. 2, pp. 113–118, 1998.

[23] World Health Organization. (2025). DDD indicators. [Online] Available: https://www.who.int/tools/atc-ddd-toolkit/indicators

[24] IBM SPSS Statistics for Windows (Version 29.0.2.0). Armonk, N.Y., United States.

[25] R. Melasari, "Evaluasi kuantitatif penggunaan obat-obat kardiovaskular di Puskesmas Sekabupaten Sleman tahun 2021," Universitas Islam Indonesia, Abstract, 2021.

[26] S. Nurhidayati, "Evaluasi penggunaan obat kardiovaskular di puskesmas se-Kabupaten Sleman pada tahun 2015-2019 dengan metode ATC/DDD dan DU 90%," Universitas Islam Indonesia, 2020.

[27] A. Rahman, "Analisis sebaran penggunaan obat-obat kardiovaskular di puskesmas se-Kabupaten Sleman pada tahun 2020.," Universitas Islam Indonesia, Abstract, 2021.

[28] X. Rossello, S. J. Pocock, and D. G. Julian, "Long-term use of cardiovascular drugs: challenges for research and for patient care," Journal of the American College of Cardiology, vol. 66, no. 11, 2015, doi: 10.1016/j.jacc.2015.07.018.

[29] Australian Institute of Health and Welfare. (2017). Medicines for cardiovascular disease. Cat. no. CVD 80.

[30] V. J. Wirtz, W. A. Kaplan, G. Kwan, and R. Laing, "Access to medications for cardiovascular diseases in low- and middle-income countries," Circulation, vol. 133, no. 21, pp. 2076–2085, 2016, doi: 10.1161/CIRCULATIONAHA.115.008722.

[31] "MIMS Drugs V3.48.2." https://www.mims.com/indonesia (accessed.

[32] Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Panduan Tata Laksana Penyakit Arteri Perifer 2024.

[33] G. H. Bevan and K. T. W. Solaru, "Evidence-based medical management of peripheral artery disease," Arterioscler Thromb Vasc Biol, vol. 40, pp. 541–553, 2020, doi: 10.1161/ATVBAHA.119.312142.

[34] Kementerian Kesehatan Republik Indonesia. (2023). Formularium Nasional. [Online] Available: https://e-fornas.kemkes.go.id

[35] Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia. (2018). Laporan Nasional Riskesdas 2018.

[36] C. Vrints et al., "2024 ESC Guidelines for the management of chronic coronary syndromes," European Heart Journal, vol. 45, 2024.

[37] I. C. van Gelder et al., "2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)," European Heart Journal, vol. 45, 2024.

[38] R. M. C. Biancatelli, V. Congedo, L. Calvosa, M. Ciacciarelli, A. Polidoro, and L. Iuliano, "Adverse reactions of amiodarone," Journal of Geriatric Cardiology, vol. 16, pp. 552–566, 2019, doi: 10.11909/j.issn.1671-5411.2019.07.004.

[39] J. Yang et al., "Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system," Front Pharmacol, vol. 16, p. 1517616, 2025, doi: 10.3389/fphar.2025.1517616.

[40] Badan Pengawas Obat dan Makanan Republik Indonesia. (2022). Cek Produk BPOM. [Online] Available: https://cekbpom.pom.go.id/all-produk?query=Brilinta

[41] PT AstraZeneca Indonesia. (2024). BrilintaTM.

Downloads

Published

2026-05-28

Issue

Vol. 7 No. 2 (2026): J. Sains Kes.

Section

Articles

License

Copyright (c) 2026 Jurnal Sains dan Kesehatan

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/jskff/public_html/plugins/generic/citations/CitationsPlugin.php on line 68

How to Cite

[1]
S. Irawati, Silvia, Deisy, I. G. A. P. Maharani, and P. A. S. P. Dewi, “Tren Konsumsi Obat Kardiovaskular di Komunitas di Surabaya Timur Selama Tahun 2020-2022: Studi Farmakoepidemiologi Deskriptif: Trend in Cardiovascular Medicine Consumption in a Community in East Surabaya from 2020 to 2022: a Descriptive Pharmacoepidemiological Study”, J. Sains. Kes, vol. 7, no. 2, pp. 24–41, May 2026, doi: 10.30872/jsk.v7i2.953.

Most read articles by the same author(s)